Patents Examined by Kortney L Klinkel
  • Patent number: 10286035
    Abstract: An ophthalmic treatment composition for the treatment of dry eye consists essentially of squalane in an amount by weight of 1% to 100%; and mineral oil in an amount by weight of 0% to 99%. Preferably, the mineral oil is a light mineral oil or mixture of light mineral oils and is present in an amount by weight of 1% to 10%. The composition is effectively devoid of water, preservatives, emulsifiers and dispersing agents. A related ophthalmic treatment composition comprises squalane in an amount by weight of 1% to 99% and mineral oil in an amount by weight of 0% to 99% and at least one hydrophobic or lipophilic pharmaceutical substance in an amount by weight of 0.01% to 5%, effective for treatment of at least one ophthalmic condition.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: May 14, 2019
    Inventor: Paul Gavaris
  • Patent number: 10266516
    Abstract: Deuterated domperidone compositions, methods of synthesis, methods of use, and dosing formulations providing beneficial safety and other effects.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 23, 2019
    Assignee: CINRX PHARMA, LLC
    Inventors: Catherine Pearce, Jon Isaacsohn, Piyush Patel
  • Patent number: 10251392
    Abstract: The present invention comprises methods and compositions for antimicrobial devices comprising metal containing compositions which are resistant to heat and light discoloration. The metal containing compositions may comprise salts or complexes of silver, copper or zinc. In one aspect the compositions comprise silver salts. In another aspect, the compositions comprise silver complexes. In one aspect, the metal salts may comprise metal salts of saccharin, acesulfame, long chain fatty acids, and alkyl dicarboxylic acids. The compositions further comprise polymers which form salts or complexes with silver, copper or zinc. The methods of the present invention comprise treating devices with the metal containing compositions, including, but not limited to, such devices as woven wound care materials, catheters, patient care devices, and collagen matrices. The present invention further comprises treatment of humans and animals with the antimicrobial devices described herein.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: April 9, 2019
    Assignee: Avent, Inc.
    Inventors: Bhalchandra M. Karandikar, Bruce L. Gibbins, Ken A. Cornell
  • Patent number: 10253027
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: April 9, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Joanne J. Bronson, Carolyn Diane Dzierba, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani
  • Patent number: 10238615
    Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: March 26, 2019
    Assignee: Bracco S.P.A.
    Inventors: Livio Cavalieri, Giovanni Rivolta, Fulvia Vella
  • Patent number: 10238600
    Abstract: A package, system and methods allow for custody and control of drugs, especially for an abuse-prone drug. A package for custody and control of a dose of an active agent, includes a unit dose of an active agent, and an individual package sealing the unit dose therein, the package having a custody and control product identifier unique to each unit dose provided on the package. A system for custody and control of a dose of an active agent, includes an individual package of one unit dose of an active agent, the package having a custody and control product identifier unique to each unit dose provided on the package, and a database containing data reflecting the custody and control identifier corresponding to each unit dose and an identifier configured to be able to identify the party to whom each unit dose is provided.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: March 26, 2019
    Inventors: Richard C. Fuisz, Joseph M. Fuisz
  • Patent number: 10233170
    Abstract: The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-? superfamily such as Nodal or Activin.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: March 19, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Donald Payan, Marina Gelman, Todd Kinsella
  • Patent number: 10227330
    Abstract: The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 12, 2019
    Assignee: YUHAN CORPORATION
    Inventors: Hyun-Joo Lee, Dong-Hoon Kim, Tae-Kyun Kim, Young-Ae Yoon, Jae-Young Sim, Myung-Hun Cha, Eun-Jung Jung, Kyoung-Kyu Ahn, Tai-Au Lee
  • Patent number: 10227357
    Abstract: Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: March 12, 2019
    Assignee: Plexxikon Inc.
    Inventors: Jack Lin, John Buell, Katrina Chan, Todd Ewing, Prabha Ibrahim, Marika Nespi, Phuongly Pham, Songyuan Shi, Wayne Spevak, Guoxian Wu, Jiazhong Zhang, Ying Zhang
  • Patent number: 10220048
    Abstract: Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: March 5, 2019
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: Kevin Peters, Robert Shalwitz
  • Patent number: 10220049
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: March 5, 2019
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Yunik Chang, Gordon J. Dow
  • Patent number: 10220039
    Abstract: A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: March 5, 2019
    Assignee: Genzyme Corporation
    Inventors: Thomas A. Natoli, Oxana Ibraghimov-Beskrovnaya, John P. Leonard, Nelson S. Yew, Seng H. Cheng
  • Patent number: 10220008
    Abstract: Using high-throughput screening, in an oxygen-glucose deprivation (OGD) model, isoxsuprine hydrochloride was identified as a potent neuroprotective compound. In an animal middle artery occlusion (MCAO) model of transient focal ischemia, isoxsuprine significantly reduced infarct volume compared to vehicle. The invention, therefore, provides methods of treatment and pharmaceutical compositions that are useful in the treatment and prevention of a wide-variety of ischemia-related injuries, including stroke.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: March 5, 2019
    Assignee: STC.UNM
    Inventor: Jeff Wade Hill
  • Patent number: 10213424
    Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: February 26, 2019
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Alain Cuine, Didier Hoarau, Pauline Romain
  • Patent number: 10213474
    Abstract: The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: February 26, 2019
    Assignee: Nanomerics LTD
    Inventors: Ijeoma Uchegbu, Andreas Schatzlein, Lisa Godfrey, Katerina Lalatsa, Antonio Iannitelli
  • Patent number: 10206919
    Abstract: The embodiments described herein include methods and formulations for treating vasculitis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 19, 2019
    Assignee: IRR, Inc.
    Inventor: Bruce Chandler May
  • Patent number: 10207020
    Abstract: An identification device that combines an antimicrobial coating with a printable substrate. For example, the invention includes a wristband with a face stock supporting indicia which are applied on (such as through thermal transfer printing) or through (such as through direct thermal printing) an antimicrobial layer. The antimicrobial layer is preferably a coating or varnish that is applied as the outermost layer and can bind with thermal transfer printing ink or supports pass through of direct thermal printing on a chemically receptive sublayer. The antimicrobial varnish includes varnish compounds and antimicrobial compounds such as a silver zeolite ion that is configured to react to moisture with a controlled release of microbial disinfectant. Preferably, the wristband is a hospital wristband bearing on-site printed identification indicia for a patient.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: February 19, 2019
    Assignee: Zebra Technologies Corporation
    Inventors: Gene Allen Hofer, David Macedon
  • Patent number: 10202370
    Abstract: Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 12, 2019
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Abdellah Benjahad, Claire Schalon, Didier Pez, Emmanuel Chevenier, Franck Sandrinelli, Jason Martin, Willy Picoul
  • Patent number: 10201537
    Abstract: The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 12, 2019
    Assignee: IRR, Inc.
    Inventor: Bruce Chandler May
  • Patent number: 10195142
    Abstract: A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: February 5, 2019
    Inventors: Richard C. Fuisz, Joseph M. Fuisz